表皮生长因子受体在头颈鳞状细胞癌广泛表达# 而且其表达水平与预后呈负相关% 因此作为B
种表皮生长因子受体抑制剂# Cetuximab 在治疗头颈鳞癌中的研究受到广泛关注 …

Cetuximab is an epidermal growth factor receptor inhibitor which has been recently focused
on the therapy of squamous cell carcinoma of the head and neck based on the nearly …

背景与目的: Cetuximab 联合放疗或化疗治疗头颈恶性肿瘤的报道不多. 本研究总结Cetuximab
与放疗或化疗联合治疗头颈恶性肿瘤的近期疗效. 方法: 选取2005 年10 月1 日至2008 年9 月30 …

分子靶向治疗是指针对细胞受体, 关键基因和调控分子为靶点的治疗, 具有与放化疗协同作用,
并逆转化疗耐药的优点. 在肿瘤的分子靶向治疗中, 针对表皮生长因子受体(epidermal growth …

Background and Objective: Cetuximab combined with radiotherapy or chemotherapy has
been used to treat head and neck cancer in recent years, but few reports are available in …

背景与目的: 头颈部鳞癌患者高表达表皮生长因子受体(epidermal growth factor receptor,
EGFR) 西妥昔单抗(cetuximab, C225, erbitux) 作为一种抗EGFR 的新型人鼠嵌合性单克隆抗体 …

As EGFR is overexpressed in over 90% of all squamous cell cancers of the head and neck
(SCCHN) there is a strong rationale supporting Epidermal Growth Factor Receptor (EGFR) …

Abstract Background: Cetuximab (Erbitux) is the only new medical therapy for locally and
regionally advanced SCCHN to be licensed in industrialized countries in the past 15 years …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

Introduction The purpose of this study was to evaluate the clinical efficacy in our daily
practice, outside clinical trials, of cetuximab plus radiotherapy in a majority of treatment …